---
title: "GlucoTrack surges 9% after hours on Lōkahi Therapeutics merger completion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292816732.md"
description: "GlucoTrack jumps 9% after hours after completing merger with Lōkahi. Lōkahi holders to own 90%, Erik Emerson named CEO. USPTO allows glucose monitoring patent."
datetime: "2026-07-15T21:01:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292816732.md)
  - [en](https://longbridge.com/en/news/292816732.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292816732.md)
generator: "portal-rs"
---

# GlucoTrack surges 9% after hours on Lōkahi Therapeutics merger completion

GlucoTrack（GCTK.US）盘后涨**8.7%**，现报**0.575 美元**。

公司已完成与 Lōkahi Therapeutics 的战略业务合并，建立由 Lōkahi 控制的公共平台。Lōkahi 安全持有人将持有合并后公司约 90% 的股份，Erik Emerson 获任 CEO。

此外，美国专利商标局已允许其可植入连续血糖监测平台专利申请，保护血管内传感技术。

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)

## Related News & Research

- [GlucoTrack amends 8-K to add accountant review report for Lokahi interim financials](https://longbridge.com/en/news/297366213.md)
- [GlucoTrack Executes Reverse Stock Split to Restructure Shares](https://longbridge.com/en/news/297372174.md)
- [GlucoTrack to enact 1-for-15 reverse stock split Aug. 31](https://longbridge.com/en/news/297181503.md)
- [GlucoTrack unit Lokahi Therapeutics starts GMP manufacturing for LT-100 osteoarthritis pain candidate](https://longbridge.com/en/news/296910729.md)
- [GlucoTrack unit Lokahi Therapeutics expands ai2 Futures Lab collaboration with University of Georgia](https://longbridge.com/en/news/296614954.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**